Mibefradil is primarily used as a calcium channel blocker, specifically targeting T-type calcium channels. Its application is mainly in the treatment of hypertension and chronic stable angina, where it helps to relax and widen blood vessels, thereby improving blood flow and reducing blood pressure. By inhibiting calcium influx into cardiac and smooth muscle cells, mibefradil reduces the workload on the heart and decreases oxygen demand, making it effective in managing these cardiovascular conditions. However, its use has been limited due to potential drug interactions and adverse effects, leading to its withdrawal from the market in many countries. Despite this, it remains a subject of research for its potential therapeutic effects in other areas, such as certain types of cancer and neurological disorders, where T-type calcium channels play a significant role.